Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 3 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 6042
Sealed predictions
- GORASP1 in dopamine neurons, braak-0.36 (p 0.344) → -0.37 (p 0.334)receipt 6050
Swarm cases
receipt 6050: GORASP1 in dopamine neurons, braak
- power
- full sample -0.41 (p 0.095, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.109, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.040, n 18). not the mix.
- skeptic
- leave-one-out range -0.58 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.095, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0053, n 18) vs -0.41 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GORASP1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GORASP1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 3.3e-4)
Receipts
loading the receipts